Tuhura Biosciences, Inc/nv 8-K filings

TuHURA Biosciences updates investors on its clinical programs, including the planned Phase 3 trial for IFx-2.0 and the acquisition of Kineta's VISTA inhibiting mAb, with key data readouts expected over the next 24 months.

TuHURA Biosciences appoints Dr. Craig L. Tendler, former Vice President at Johnson & Johnson Innovative Medicine, to its Board of Directors, effective March 10, 2025.

TuHURA Biosciences receives $3.01 million from warrant exercises, funded by secured promissory notes bearing 12% interest.

TuHURA Biosciences, formerly Kintara Therapeutics, has appointed Cherry Bekaert LLP as its new independent auditor, replacing Marcum LLP, following the completion of a merger.

TuHURA Biosciences has entered into a definitive agreement to acquire Kineta, gaining access to a Phase 2 novel checkpoint inhibitor and expanding its immuno-oncology pipeline.

TuHURA Biosciences is advancing its lead candidate, IFx-2.0, into a Phase 3 trial and has entered a non-binding letter of intent for a potential merger with Kineta, Inc.

TuHURA Biosciences has increased the base salaries of its CEO and CFO and granted them significant stock options, effective January 1, 2025.

TuHURA Biosciences has amended its previous 8-K filing to incorporate the financial results of the private company, TuHURA, for the periods ending September 30, 2024, and 2023, following its merger with Kintara Therapeutics.

TuHURA Biosciences finalized its merger with Kintara Therapeutics, now operating as TuHURA Biosciences, focusing on novel technologies to combat cancer immunotherapy resistance.

Kintara Therapeutics has corrected the record date for the distribution of Contingent Value Rights (CVRs) to its stockholders, linking it to the reverse stock split rather than a previously announced date.

Kintara Therapeutics has announced October 17, 2024, as the record date for the issuance of Contingent Value Rights (CVRs) to its stockholders, preceding the expected merger with TuHURA Biosciences on October 18, 2024.

Kintara Therapeutics and TuHURA Biosciences are merging, with TuHURA surviving as a wholly-owned subsidiary of Kintara, and this report provides unaudited financial statements for TuHURA and pro forma financials for the combined entity.

Kintara Therapeutics reported its fiscal year 2024 financial results, highlighted by a reduced net loss and the approval of its merger with TuHURA Biosciences.

Kintara Therapeutics stockholders approved several key proposals related to its merger with TuHURA Biosciences, including the issuance of merger shares and a reverse stock split, but did not approve an increase in authorized shares or a change of state of incorporation.

Kintara Therapeutics and TuHURA Biosciences have amended their merger agreement, waiving the requirement for Kintara stockholder approval of reincorporation and an increase in authorized shares, contingent on a reverse stock split.

Kintara Therapeutics has adjourned its Special Meeting of Stockholders to October 4th due to insufficient votes for the proposed merger with TuHURA Biosciences, urging all stockholders to vote by the October 3rd deadline.

Kintara Therapeutics has adjourned its special stockholder meeting to October 4th due to a lack of sufficient votes to approve proposals related to a merger with TuHURA Biosciences, a reverse stock split, and an increase in authorized shares.

Kintara Therapeutics and TuHURA Biosciences shared updates on their proposed merger through social media posts, highlighting the upcoming Special Meeting of Stockholders.

Kintara Therapeutics is reminding stockholders to vote by September 19, 2024, to approve the proposed merger with TuHURA Biosciences.

Kintara Therapeutics is urging shareholders to vote in favor of a proposed merger with TuHURA Biosciences, while also providing an update on their REM-001 clinical study.

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences at the upcoming Special Meeting.

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences, emphasizing the potential consequences of not approving the merger.

Kineta has reopened enrollment for its VISTA-101 Phase 1/2 clinical trial, evaluating KVA12123, a VISTA blocking antibody, in patients with advanced solid tumors, while TuHURA Biosciences conducts due diligence for a potential acquisition.

Kintara Therapeutics has withdrawn the designations of its Special Voting Preferred Stock and Series B Preferred Stock, effective July 12, 2024.

TuHURA Biosciences has entered into an agreement with Kineta for exclusive rights to acquire Kineta's KVA12123 anti-VISTA antibody, a novel checkpoint inhibitor, while also securing a $5 million private investment.

Kintara Therapeutics and TuHURA Biosciences provided an update on their merger, clinical advancements, and upcoming milestones, including a Phase 3 trial for TuHURA and continued enrollment in Kintara's REM-001 study.

Kintara Therapeutics successfully held its annual meeting, electing directors, approving executive compensation, and ratifying the appointment of its accounting firm.

Kintara Therapeutics has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, while also progressing with its proposed merger with TuHURA.

TuHURA Biosciences and Kintara Therapeutics announced positive results from a Phase 1b trial of IFx-2.0, a personalized cancer vaccine, and detailed their planned merger.

Kintara Therapeutics reported its third quarter fiscal 2024 financial results, highlighted by a reduced net loss and announced a merger agreement with TuHURA Biosciences.